← Back to all trials
Completed
NCT04848272
Inhibition of Plasma Kallikrein as a New Therapy for Lung Injury
Conditions: Lung Injury
Sex: All
Ages: 18 Years – 90 Years
Healthy volunteers: No
Phase: PHASE1
Enrollment: 35
Sponsor: St Vincent's Institute of Medical Research
Location: St Vincent's Hospital Melbourne Melbourne Victoria
Summary
Phase 1 study investigating safety of lanadelumab administration to patients with lung injury
Eligibility Criteria
Inclusion Criteria:
* Age \>18 years admitted to the ICU with primary diagnosis of lung injury. The criteria for the diagnosis of lung injury include five principal elements: hypoxemia (blood oxygen saturation (PaO2) ≤92% when breathing ambient air, ratio of PaO2 to the fraction of inspired oxygen (FiO2) ≤300), diffuse pulmonary infiltrates on chest radiographs, decreased lung compliance, and the absence of congestive heart failure.
* Both males and females will be recruited in the proportion in which they are admitted to the ICU with lung injury.
* Arterial cannula in place as part of usual care for the measurement of blood gases.
* Patients may or may not be intubated and mechanically ventilated.
* Able to provide informed consent, or if unable to do so, a responsible person:
medical treatment decision maker is available (by telephone if necessary) who can be approached to seek consent.
Exclusion Criteria:
* Other causes of lung infiltrates: pulmonary oedema, alveolar haemorrhage, adverse drug reactions, radiation injury and the idiopathic pneumonitis syndrome.
* Significant dysfunction of non-pulmonary organs in the opinion of the treating ICU consultant.
* Death is deemed imminent or inevitable or there is underlying disease with a life expectancy of less than 90 days.
* Previously enrolled in this study.
* Enrolled in another study.
* Usually receives home oxygen.
* Usually receives any type of assisted ventilation at home. e.g. continuous positive airway pressure for obstructive sleep apnoea.
* Pregnant or might be pregnant. Women aged 18 to 49 are excluded unless there is documented menopause, hysterectomy or surgical sterilisation, or a pregnancy test is negative.
* Objection from the treating clinician.
* Consent refused by the patient or substitute decision maker.
Source: ClinicalTrials.gov (NCT04848272). StuddyBuddy aggregates publicly available trial information.